Self-Assembling Vaccines (SAV): Precision-Targeted, Potent, and Rapidly Deployable

Next-generation vaccine architecture engineered to enhance immune performance and reduce development time across oncology and infectious disease indications.

  • Next Generation Vaccine Architecture

  • Enhanced immune performance
  • Reduced Development time
  • Studied in infectious diseases and oncology

A Modular Two-Part System: Fixed Backbone + Custom Payload

  • Fixed Component: MAV (MtbHSP-70 fused with Avidin)
    • Pre-manufactured, stockpileable, universal carrier
  • Variable Component: Biotin-tagged antigens
    • Peptides, proteins, small molecules, monoclonal antibodies, etc.

Built for Speed, Flexibility, and Scale

  • CHO-based GMP production of MAV fusion protein
  • Click chemistry and solid-phase synthesis for scalable biotinylated peptides
  • Cross-product manufacturing streamlines CMC risk and cost

SAV is Different and Better

  • Superior immune response vs. gold standard Alum

  • Engages both CD8+ and CD4+ T cells

  • Highly modular for combo therapies or repurposed antigens

  • Intradermal administration enhances dendritic cell activation

  • Stable at refrigerated temperatures

 

Validated in Models of Aggressive Tumors and Infectious Pathogens

  • SAV platforms show increased survival and tumor suppression in HPV-positive tumor models

  • No dose-limiting toxicities observed to date

  • DoD-funded programs reinforce confidence in platform scalability